Pear portfolio company BioAge Labs announces oversubscribed $170M Series D financing

Last week, Pear portfolio company BioAge Labs announced its $170M Series D round led by Sofinnova Investments, with participation from a strong syndicate of new investors including Longitude Capital, RA Capital, OrbiMed Advisors, RTW Investments, Eli Lilly, and Amgen, among others, in addition to many existing investors. 

To mark this occasion, we wanted to share more about Pear’s partnership with BioAge Labs and its co-founders, Kristen Fortney (CEO) and Eric Morgen (COO). 

Pear’s founders, Pejman and Mar, first met Kristen in 2015 through an introduction by another company founder associated with the Stanford Genome Technology Center. At that time, Kristen was a postdoc at Stanford in Professor Stuart Kim’s lab, where she studied the genetics of extreme human longevity. At the time, Kristen had published extensively in the space of genetics and longevity, but the company was merely an idea. She was pondering the question: could we use genetic information and new machine learning techniques to develop a therapy discovery platform for longevity? Kristen’s vision at the time was just as clear as it is today. 

That year, Pear invested in BioAge’s initial seed financing, and we have gone on to successively back BioAge at every subsequent round, including the Series D. 

As it’s not common for a seed-stage focused firm like ours to invest up until the Series D round, why have we continued to support BioAge?

Significant unmet need and large market opportunity in obesity and metabolic disease

The company’s lead drug program, azelaprag, addresses obesity and metabolic diseases. A staggering 40% of American adults are considered obese, and many suffer from a host of comorbidities including diabetes, heart disease, and stroke.

One of the most exciting recent medical advances has been the remarkable success of GLP-1 receptor agonist drugs in achieving dramatic weight loss in such patients, while still being generally safe and well tolerated.

With this drug class expected to eventually exceed $150 billion in sales annually, the top two developers, Eli Lilly and Novo Nordisk, have catapulted to become the first and second largest pharma companies by market capitalization (~$740B and $550B, respectively, as of mid-Feb. 2024). 

As impressive as GLP-1 drugs are, one downside is that they can result in suboptimal body composition, in that they lead to the loss of both fat and muscle. BioAge’s preclinical studies have shown that azelaprag, which is a first-in-class oral apelin receptor agonist, can enhance body composition when combined with a GLP-1 drug. In a Phase 1b study sponsored by BioAge, azelaprag prevented muscle deterioration and promoted muscle metabolism in healthy older volunteers at bedrest.

A second limitation is that oral GLP-1 drugs have so far lagged behind the injectable versions in efficacy. Of course, most patients would strongly prefer orally dosed medications over injectables. In BioAge’s preclinical studies, azelaprag combined with a GLP-1 drug has been shown to double the weight loss achieved by the GLP-1 drug alone. Because it can be orally administered and has been well tolerated, azelaprag in combination with an oral GLP-1 drug may help to close this efficacy gap.

Human-first target discovery platform enabled by multi-omic analysis of aging human cohorts 

BioAge didn’t initially begin with a focus on a lead therapeutic asset in obesity. In fact, BioAge started as a target discovery company within the longevity space, with the ambitious goal of understanding the biology of human aging in an effort to extend human lifespan and healthspan. 

Although the longevity field has recently attracted much attention and investment, not all therapeutic strategies pursued have been equally scientifically rigorous. Many approaches rely on attempting to translate into humans tantalizing life extension or rejuvenation effects obtained in model organisms with very short lifespans like nematodes and mice.

But the biology of aging differs dramatically across species, and BioAge’s unique strategy was to partner with special biobanks that collected and stored blood from cohorts of people from middle age until death and that retained associated health records. By deploying multi-omics (primarily proteomics) and AI to interrogate the factors correlating with healthy human aging, the company generated unique insights into particular therapeutic targets of interest. 

From this platform, one of the strongest targets that emerged was the peptide that azelaprag is designed to mimic – apelin. Exercise stimulates release of apelin from skeletal muscle into the blood, and in BioAge’s cohorts, middle-aged people with more apelin signaling were living longer, with better muscle function, and better brain function. Correspondingly, in mice, azelaprag protected elderly mice from muscle atrophy & preserved function in vivo

Strong leadership team, advisors, and partners

As one might imagine, the team at BioAge has grown and matured substantially since inception in 2015. The leadership team today has world-class experience across biopharma. And in pursuing its Phase 2 study of azelaprag in combination with Eli Lilly’s GLP-1/GIP drug tirzepatide (Zepbound), BioAge will receive support from Eli Lilly’s Chorus organization, including the supply of tirzepatide and clinical trial design and execution expertise.  

It’s certainly uncommon for a postdoc straight out of the lab to lead a therapeutics company until a Phase 2 clinical study. But as Kristen relayed during a fireside chat at our Pear office, she learned a lot about what she needed to know on the job progressively over time, and she was not afraid to surround herself with experts specializing in the many functional domains required to take a drug program from a target to the clinic. 

This dedication to continual self-improvement and learning has been a hallmark of the many strong founders that we are fortunate to back at Pear. We are grateful that Kristen is helping to guide the next generation of such founders as part of our Pear Biotech Industry Advisory Council.

Pear Biotech Industry Advisory Council

For these reasons, we remain excited to support BioAge Labs. We eagerly anticipate the results of its mid-stage clinical trials of azelaprag in obesity, as well as the development of additional programs nominated from its unique human aging target discovery platform. 

Pear Biotech Bench to Business: insights on the past, present, and future of synthetic biology with Dr. Jim Collins

Here at Pear, we specialize in backing companies at the pre-seed and seed stages, and we work closely with our founders to bring their breakthrough ideas, technologies, and businesses from 0 to 1. Because we are passionate about the journey from bench to business, we created this series to share stories from leaders in biotech and academia and to highlight the real-world impact of emerging life sciences research and technologies. This post was written by Pear Partner Eddie and Pear PhD Fellow Sarah Jones.

Today, we’re excited to share insights from our discussion with Dr. Jim Collins, Termeer Professor of Medical Engineering and Science at MIT. Jim is a member of the Harvard MIT Health Sciences Technology faculty, a founder of the Wyss Institute for Biologically Inspired Engineering at Harvard, and a member of the Broad Institute of MIT. His work has been recognized with numerous awards and honors over the course of his career, such as the MacArthur “Genius” Award and the Dickson Prize in Medicine.

Hailed as one of the key pioneers of synthetic biology, Dr. Collins has not only published numerous high-profile academic papers, but also has a track record of success as a founder and as an entrepreneur, co-founding companies such as Synlogic, Senti Biosciences, Sherlock Biosciences, Cellarity, and Phare Bio. If all that wasn’t enough, he’s even thrown the first pitch at a Boston Red Sox game. We were lucky to sit down and chat with Jim about his experiences and his perspective on the future of synthetic biology. 

If you prefer listening, here’s a link to the recording! 

Key takeaways:

1. At its conception, synthetic biology was simply a ‘bottom-up’ approach to molecular biology utilized by collaborative, interdisciplinary scientists. 

  • In the late 90’s, Jim’s focus in biology began to shift: rather than continuing to explore biology at the whole organism or tissue level, he found himself more excited about molecular-scale biology. After speaking with some bioengineering faculty members at Boston University who were interested in his background in physics and engineering, Jim was quickly invited to join the department. From there, his interest in designing and engineering natural networks and biological processes flourished. 
  • At that time, however, bioengineers weren’t yet able to reverse engineer biological systems and exert precise control at the molecular scale. He asked, 

Could we take a bottom-up approach to molecular biology? Could we build circuits from the ground up as ways to both test our physical and mathematical notions and also to create biotech capabilities?

  • Though it didn’t start out as a quest to launch a new scientific field, Jim’s work contributed heavily to what would become the foundation of synthetic biology. He noted the value in bringing together scientists with diverse backgrounds to work on the same problems; for example, neuroscience had greatly benefitted from the introduction of mathematical models to describe complex neural systems. In a similar way, physicists, mathematicians, and molecular biologists began to find themselves interested in the same sorts of complex biological questions that could not be answered by any one discipline alone. 
  • Jim also acknowledged that in the early days, the tools to engineer gene networks and molecular pathways did not exist, yet his team could envision a future in which gene networks could be described and designed using elegant mathematical models and a modular set of biological tools. This goal helped to propel synthetic biology into existence.

2. The ability to program genetic circuits marked the beginning of synthetic biology and allowed efforts within the field to quickly progress. 

  • One notable 1995 publication in Science authored by Lucy Shapiro and Harley McAdams that was titled ‘Circuit simulation of genetic networks’ helped to shape Jim’s efforts in programming genetic circuits. The paper explored parallels between electrical circuits and genetic circuits and used mathematical modeling to accurately describe the bacteriophage lambda lysis-lysogeny decision circuit. In this circuit, bacteriophages that have infected bacteria cells must decide whether they are going to kill the cell or remain dormant, sparing the cell’s life.
  • Such work helped to bridge the gap between bioengineering and molecular biology at a time when many bioengineers felt largely excluded from the world of molecular biology.
  • To prove that genetic engineering was possible, the Collins lab worked to develop a genetic toggle switch in the form of a synthetic, bi-stable regulatory genetic network that could be switched ‘on’ or ‘off’ by applying heat or a particular chemical stimuli. This is significant because researchers could now add well-defined genetic networks to cells in order to precisely control their behavior or output.
  • This work by Gardner et al. was published in 2000 in the prestigious scientific journal, Nature and was titled “Construction of a genetic toggle switch in Escherichia coli.” Interestingly, in the same issue of Nature, work by Mike Elowitz’s lab at Caltech also outlined the development of a synthetic gene circuit in E. coli. Their system, dubbed the ‘Repressilator,’ was also a regulatory network in which three feedback loops could oscillate over time and change the status of the cells. Basically, it was three genes in a ring where gene A could inhibit gene B, which could inhibit gene C, which could then inhibit gene A, creating an oscillatory network. 
  • This critical body of work and scientific discovery both demonstrated that genetic engineering was possible and highlighted tools and methods that could be used to modulate molecular systems. 

3. To expand the repertoire of synthetic biology, Jim has co-founded two companies, Synlogic and Senti Biosciences, that are aimed at targeting the gut microbiome and engineering the mammalian system.

  • While initial excitement for synthetic biology applications centered on biofuel generation, the small scale bioreactors were never a match for fossil fuel companies. The paradigm in synthetic biology started shifting away from biofuel generation in the early 2000s to focus on the microbiome and its role in human disease. 
  • As local venture capitalists approached Jim and asked about what could actually be done with synthetic biology, it became clear to Jim that there were two main directions he could pursue. 

One was…an opportunity to create a picks and shovels company in synthetic biology. So, coming to create additional components or capacity to address a broad range of indications and applications, be it biofuels, industrial applications, therapeutics. The second was that you could engineer microbes to be living therapeutics, and in some cases, living diagnostics.

  • Jim partnered with Tim Lu, his former student and eventual coworker at MIT, to start Synlogic. One early direction of Synlogic was tackling a rare genetic metabolic disorder, phenylketonuria (PKU), that causes the amino acid phenylalanine to build up in the body. The idea was that they could engineer a microbe that could break down this byproduct and thereby eliminate the negative effects of the disease. This approach relied on the ability of the synthetic biologist to directly harness and control cell behavior via genetic engineering. 
  • Synlogic is also working on enzymes that produce therapeutic molecules instead of degrading toxic ones. The company now has efforts in inflammatory bowel disease and Lyme disease and has partnered with Roche to advance its pipeline. 
  • By around 2015, synthetic biology had continued to grow as an academic discipline and had moved beyond microbes to mammalian cells. Jim had since moved his lab from Boston University to MIT, and it wasn’t long before he was once again collaborating with Tim Lu, this time to apply synthetic biology in a mammalian system. This marked the start of Senti Biosciences, a company aimed at creating ‘smart medicines’ using genetic circuits.

We began to consider the possibility that we could do a mammalian version of Synlogic. Could we begin to really advance the development of human cell therapy and gene therapy using synthetic genes and gene circuits to create smart medicines? Having therapeutics that could sense their environment, sense the disease state or sense the disease target and produce therapeutics in a meaningful, decision-making way… was an exciting notion.

4. Historically, a lack of support from the venture community and insufficient infrastructure have been challenges for the diagnostics space.

  • Another company Jim helped start, Sherlock Biosciences, also leverages synthetic biology but operates in the diagnostic space. Although the diagnostic space is a notoriously challenging one, Sherlock was founded with the goal of combining approaches from synthetic biology and CRISPR technology to develop next-generation molecular diagnostics for at-home tests.
  • While many of the companies started right before the COVID-19 pandemic ultimately didn’t make it long-term, the team at Sherlock was able to quickly pivot and develop a CRISPR-based COVID-19 diagnostic that gained FDA-approval in May 2020. Notably, this test was the very first FDA-approved CRISPR product. 
  • Jim explained that the difficulties facing a company trying to operate in the diagnostics space are twofold:
    • (1) there is a lack of infrastructure for things like at-home testing, point-of-care testing, or nucleic acid tests
    • (2) there is a general lack of support for diagnostic companies in the venture community
  • Diagnostics companies are essentially valued as a multiple of revenue. In contrast, therapeutic companies can be valued based on projections 10-20 years in the future without the requirement of existing revenue. Combine this with the fact that wins tend to be much larger in the therapeutics space, diagnostic discovery and development have largely been set to the side. 
  • While COVID-19 did help to bring interest to the sector, funding and infrastructure continue to limit breakthroughs in diagnostics. 

5. Desperate for new antibiotics: a combination of synthetic biology, Machine Learning (ML) and in silico modeling has so far been fruitful.

  • With a challenging funding landscape, antibiotics have also been long-neglected by VC and industry. Despite this, Jim’s team was able to secure funding through The Audacious Project, a philanthropic effort put together by TED to support their work in antibiotic discovery. The funded project involved developing deep learning based models that could both discover and design novel antibiotics against some of the world’s nastiest pathogens. In fact, the team found success when they discovered a very powerful antibiotic called halicin. 
  • Recently published in Nature, an article by the Collins lab highlights their continued efforts in the “Discovery of a structural class of antibiotics using explainable deep learning.” 
  • Jim stressed the urgency for new antibiotic development: the pipeline has been drying up, but the demand has only increased. Acquired antibiotic resistance is also a significant problem that hasn’t yet been resolved.
  • As new, powerful antibiotics are developed, they become the last-line of defense against the worst, most deadly pathogens. However, drugs used as a last-line of defense don’t make it off the shelves very often: this means that there is less financial motivation to develop particularly potent antibiotics. To address this, Jim noted that we are going to need a new financial model to sufficiently support research in this space.

6. Past the hype cycle: the synthetic biology of tomorrow.

  • The field has experienced its fair share of ups and downs. In speaking with Jim, it’s clear that the roller coaster of high expectations and disappointing failures has not diminished his excitement about the future of synthetic biology. 
  • In 2004, the initial hype cycle was centered on biofuels and their potential to replace fossil fuels. Unrealistic expectations combined with the high cost of biofuel production led to disappointment; people began to question whether or not synthetic biology could deliver. 
  • In the second hype cycle, bold claims and an attitude that synbio could solve every problem in the world led to yet another massive let-down and shift in attitude towards the field. 

I think the markets haven’t kept pace with the public statements that are being made by some of the high priests in the field. And that’s a shame. I do think synthetic biology will emerge as one of the dominant technologies of this century. Our ability to engineer biology gives us capabilities that can address many of the big challenges that we have. But it’s still going to take a lot of time, it’s still very hard to engineer biology, and biology is not yet an engineering discipline.

  • Successes in areas where biology still outcompetes chemistry have helped to put some points back on the board for synthetic biology. Increasing utilization in therapeutic development has leveraged the efficiency of biological systems and will help to pave the way for the next way of discoveries in the field. 
  • Technologies like cell-free systems also have Jim excited about the future of synthetic biology. 

Get to know Jim Collins: 

Early career and developing a passion for science: 

  • Jim comes from a family of engineers and mathematicians and has always found himself wanting to do science. Jim explained that when he was four years old, his dad was a part of a team that designed an altimeter for Apollo 11. 
  • Another seminal event that influenced Jim’s decision to become a scientist was the decline of his grandfather’s health after a series of strokes left him hemiplegic. After watching someone he loved not receive the care or have treatment options that could restore function, Jim was inspired to pursue biomedical engineering. 
  • Once he realized that he could interface with clinicians, entrepreneurs, and policy-makers as a professor, he realized that was the path for him.

Advice for early-stage founders:

  • Find a strong business team early on to help find market fit and to guide the development of your final product. Young scientists are not trained to be good CEO’s, and it’s often challenging to navigate these decisions if you don’t have the experience.
  • Make sure your strategy has a real market pull and is differentiated from other approaches.  

Perspectives in AI with Kamil Rocki, Head of Performance Engineering at Stability AI

At Pear, we recently hosted a Perspectives in AI fireside chat with Kamil Rocki, Head of Performance Engineering at Stability AI. We discussed breakthroughs at the hardware-software interface that are powering generative AI. Kamil has extensive experience with GPU hardware and software programming from his PhD research and his work at IBM, Nvidia, Cerebras, Neuralink, and of course now StabilityAI. Read a recap of that conversation below:

Aparna: Kamil, thank you for joining us. You’ve accomplished many amazing things in your career, and we’re excited to hear your story. How did you choose your career path and what led you to work on the projects you’ve been involved with?

Kamil: My journey into the world of technology began in my 20s. After a few years of rigorous mathematical studies, I found myself in a robotics lab. I was tasked with enabling a robot to solve a Rubik’s cube. The challenge was to detect the cube’s location in an image captured by a camera, and this had to be done at a rate of 100 frames per second. 

I was intrigued by the work my peers were doing in computer graphics using Graphics Processing Units (GPUs). They were generating landscapes and waves, manipulating lighting, and everything was happening in real-time. This inspired me to use GPUs to process the images for my project.

The process was quite challenging. I had to learn OpenGL from my friends, write images to the GPU, apply a pixel shader, and then read data back from the GPU. Despite the complexity, I was able to exceed the initial goal and run the process at 200 frames per second. I even developed a primitive version of a neural network that could detect the cube’s location in the image.

In 2008, around the time I graduated, CUDA came out and there was a lot of excitement around GPUs. I wanted to continue exploring this field and heard about a supercomputer being built in Japan based on GPUs and ended up doing a PhD in supercomputing. During this time, I worked on an algorithm called Monte Carlo Tree Search, deploying it on a cluster of 256 GPUs. At that time, not many people were familiar with GPU programming, which eventually led me to the Bay Area and IBM Research in Almaden.

I spent five years at IBM Research, then moved to the startup world. I had learned how to build chips, design computer architecture, and build computers from scratch. I was able to go from understanding the physics of transistors to building a software stack on top of that, including an assembler, compiler, and programming what I had built. One of my goals at IBM was to develop a wafer scale system. This led me to Cerebras Systems, where I co-designed the hardware. Later I joined Neuralink and then Nvidia, where I worked on the Hopper architecture. I joined Stability, as we are currently in a transition to Hopper GPUs. There is a significant amount of performance work required, and with my extensive experience with this architecture, I am well-equipped to contribute to this transition.

Aparna:  GPUs have become one of the most profitable segments of the AI value chain, just looking at Nvidia’s growth and valuation. GPUs are also currently a capacity bottleneck. How did we arrive at this point? What did Nvidia, and others, do right or wrong to get us here?

Kamil: Nvidia’s journey to becoming a key player in the field of artificial intelligence is quite interesting. Initially, Nvidia was primarily known for its Graphics Processing Units (GPUs), which were used in the field of graphics. A basic primitive in graphics involves small matrix multiplication, used for rotating objects and performing various view projection transformations. People soon realized that these GPUs, efficient at matrix multiplications, could be applied to other domains where such operations were required.

In my early days at the Robotics Lab, I remember working with GPUs like the GeForce 6800 series. These were primarily designed for graphics, but I saw potential for other uses. I spent a considerable amount of time writing OpenGL code to set up the entire pipeline for simple image processing. This involved rasterization, vertex shader, pixel shader, frame buffer, and other complex processes. It was a challenging task to explore the potential of these GPUs beyond their conventional use.

Nvidia noticed that people were trying to use GPUs for general-purpose computing, not just for rendering images. In response, they developed CUDA, a parallel computing platform an application programming interface model. This platform significantly simplified the programming process. Tasks that previously required 500 lines of code could now be achieved with a program that resembled a simple C program. This opened up the world of GPU programming to a wider audience, making it more accessible and flexible.

Around 2011-12, the ImageNet moment occurred, and people realized the potential of scaling up with GPUs. Before this, CPUs were the primary choice for most computing tasks. However, the realization that GPUs could perform the same operations on different data sets significantly faster than CPUs led to a shift in preference. This was particularly impactful in the field of machine learning, where large amounts of data are processed using the same operations. GPUs proved to be highly efficient at performing these repetitive tasks.

This realization sparked a self-perpetuating cycle. As GPUs became more powerful, they were used more extensively in machine learning, leading to the development of more powerful models. Nvidia continued to innovate, introducing tensor cores that further enhanced machine learning capabilities. They were smart in making their products flexible, catering to multiple markets including graphics, machine learning, and high-performance computing (HPC). They supported FP64 computation, graphics, and tensor cores, which could be used for ray tracing and FP64. This adaptability and flexibility, combined with an accessible programming model, is what sets Nvidia apart in the field.

In the span of the last 15 years, from 2008 to the present, we have seen a multitude of different architectures emerge in the field of machine learning. Each of these architectures was designed to be flexible and adaptable, capable of being executed on a GPU. This flexibility is crucial as it allows for a wide range of operations, without being limited to any specific ones.

This approach also empowers users by not restricting them to pre-built libraries that can only run a single model. Instead, it provides them with the freedom to program as they see fit. For instance, if a user is proficient in C, they can utilize CUDA to write any machine learning model they desire.

However, some companies have lagged behind in this regard. Their mistake was in not providing users with the flexibility to do as they please. Instead, they pre-programmed their devices and assumed that certain architectures would remain relevant indefinitely. This is a flawed assumption. Machine learning architectures are continuously evolving, and this is a trend that I foresee continuing into the future.

Aparna: Could you elaborate more on the topic of special purpose chips for AI? Several companies, such as SambaNova Systems and Cerebras, have attempted to develop these. What, in your opinion, would be a successful architecture for such a chip? What would it take to build a competitive product in this field? Could you also shed some light on strategies that have not worked well, and those that could potentially succeed?

Kamil: Reflecting on my experience at Cerebras Systems, I believe one of the major missteps was the company’s focus on building specialized kernels for specific architectures. For instance, when ResNet was introduced, the team rushed to develop an architecture for it. The same happened with WaveNet and later, the Transformer model. At one point, out of 500 employees, 400 were kernel engineers, all working on specialized kernels for these architectures. The assumption was that these models were fixed and optimized, and users were simply expected to utilize our library without making any changes.

However, I believe this approach was flawed. It did not take into account the fact that architectures change frequently. Every day, new research papers are published, introducing new models and requiring changes to existing ones. Many companies, including Cerebras, failed to anticipate this. They were so focused on specific architectures that they did not consider the need for flexibility.

In contrast, I admire NVIDIA’s approach. They provide users with tools and allow them to program as they wish. This approach is more successful because it allows for adaptability. Despite the progress made by companies like Cerebras, Graphcore, and others, I believe too much time and effort is spent on developing prototypes of networks, rather than on creating tools that would allow users to do this work themselves.

Even now, I see companies building accelerators for the Transformer architecture. I would advise these companies to rethink their approach. They should aim for flexibility, ensuring that their architecture can accommodate changes. For instance, if we were to revert to recurrent nets in two years, their architecture should still be programmable.

Aparna: Thank you for your insights. Shifting gears, I’d like to talk about your work at Stability. It’s an impressive company with a thriving open-source community that consistently produces breakthroughs. We’ve observed the quality of the models and the possibilities with image generation. Many founders are creating companies using Stability’s models. So, my question is about the future of this technology. If a founder is building in this space and using your models as a foundation, where do you see this foundation heading? What’s the future of image generation technology at Stability?

Kamil: The potential of technology, particularly in the field of artificial intelligence, is immense. Currently, we’re seeing significant advancements in image generation models. The quality of these generated images is often astounding, sometimes creating visuals that are beyond reality, thereby accelerating creativity and content creation. We’re now extending this capability into 3D and video space. We’re actively working on models that can generate 3D scenes or objects and extend to video space. Imagine a scenario where you can generate a short clip of a dog running or even create an entire drama episode from a script.

We’re also developing audio models that can generate music. This can be combined with video generation to create a comprehensive multimedia experience. These applications have significant potential in the entertainment industry, from content generation for artists to the movie industry and game engine development.

However, I believe the real breakthrough will come when we move towards more industrial applications. If we can generate 3D representations and add video to that, we could potentially use this technology to simulate physical phenomena and accelerate R&D in the manufacturing space. For instance, generating an object that could be printed by a 3D printer. This could optimize and accelerate prototyping processes, potentially revolutionizing supply chains.

Recently, I was asked if a space rocket could be designed with generative AI. While it’s not currently feasible, the idea is intriguing and could potentially save a lot of money if we could solve complex problems using this technology.

In relation to hardware, I believe that generative AI and language models can be used to accelerate the discovery of new kinds of hardware and for generating code to optimize performance. With the increasing complexity and variety of models and architectures, traditional approaches to optimizing code and performance modeling are struggling. We need to develop more automated, data-driven approaches to tackle these challenges.

Aparna: You’ve broadened our understanding of the potential of generative AI. I’d like to delve deeper into the technical aspects. As the head of Performance Engineering at Stability, could you elaborate on the challenges involved in building systems that can generate video and potentially manufacture objects without error, performing exactly as intended?

Kamil: From a performance perspective, the issue of being limited by computational resources is closely related to the first question. At present, only a few companies can afford to innovate due to the high costs involved.  

This situation might actually be beneficial as it could spark creativity. The scarcity of resources, particularly GPUs, could trigger innovations on the algorithmic side. I recall a similar situation in the early days of computer science when people were predicting faster clock speeds as the solution to performance issues. It was only when they hit a physical limit that they realized the potential of parallelization, which completely changed the way people thought about performance.

Currently, the cost of building a data center for training state-of-the-art language models is approaching a billion dollars, not including the millions of dollars required for training. This is not a sustainable situation. I miss the days when I could run models and prototype things on a laptop.

One of the main problems we face is that we’ve allowed our models to become so large, assuming that compute infrastructure is infinite. These larger models are becoming slower because more time is spent on moving data around rather than on the actual computation. For instance, when I was at Nvidia, anything below 90% of the so-called ‘speed of light’ was considered bad. However, in many cases, large language models only utilize about 30-40% of the peak performance that you can achieve on a GPU. This means a lot of compute power is wasted.

People often overlook this issue. When I suggest optimizing the code on a single GPU and running it on a small model before scaling up, many prefer to simply run it on multiple GPUs to make it faster. This lack of attention to optimization is a significant concern.

Aparna: As we wrap up, I’d like to pose a final question related to your experience at Neuralink, a company focused on brain-to-robot interaction. This technology has potential applications in assisting differently-abled individuals. Could you share your perspective on this technology? When do you anticipate it will be ready, and what applications do you foresee?

Kamil: My experience at Neuralink was truly an exciting adventure. I had the opportunity to work with a diverse team of neuroscientists, physicists, and biologists, all of whom were well-versed in computing and programming. Despite the initial intimidation, I found my place in this team and contributed to some groundbreaking work.

One of the primary challenges we aimed to address at Neuralink was the communication barrier faced by individuals whose cognitive abilities were intact, but who were physically unable to express themselves. This issue is exemplified by renowned physicist Stephen Hawking, who could only communicate by typing messages very slowly using his eyes.

Our initial project involved training macaque monkeys to play a Pong game while simultaneously feeding data from their motor cortex. This allowed us to decode brain signals and enable the monkeys to control something on the screen. Although it may not seem directly related to human communication, this technology could potentially be used to control a cursor and type messages, thus bypassing physical limitations.

We managed to measure the information transfer rate from the brain to the machine in bits per second, achieving a rate comparable to that of people typing on their cell phones. This was a significant milestone and one of the first practical applications of our technology. It could potentially benefit individuals who are paralyzed due to spinal injuries, enabling them to communicate despite their physical limitations.

However, our work at Neuralink wasn’t limited to decoding brain signals and reading data. We also explored the possibility of stimulating brain tissue to induce physical movements or visual experiences. This bidirectional communication could potentially allow individuals to interact with computers more efficiently, bypassing the need for physical input devices. It could even pave the way for a future where VR goggles are obsolete, as we could stimulate the visual cortex directly. However, the safety of these techniques is still under investigation, and it’s crucial that we continue to prioritize this aspect as we push the boundaries of what’s possible.

There’s a significant spectrum of disorders that this technology could address, particularly for individuals who struggle with mobility or communication. We were also considering mental health issues such as depression, insomnia, and ADHD. One of the concepts we were exploring is the ability to read data from the brain, identify its state, and stimulate it. This could potentially serve as a substitute for medication or other forms of treatment.

However, it’s important to note that the technology, while progressing, is not entirely clear-cut. The safety aspect is crucial and cannot be ignored. At Neuralink, we’ve done a remarkable job ensuring that everything we develop is safe, especially considering these devices are implanted in someone’s head.

When we consider brain stimulation, we must also consider potential negative scenarios. For instance, if we stimulate a certain region of the brain to alleviate depression, we could inadvertently create a dependency, similar to injecting dopamine. This could potentially lead to a loop where the individual becomes addicted to the stimulation. It’s a complex issue that requires careful consideration and handling.

In addressing these challenges, we’ve engaged in extensive conversations with physicians, neuroscientists, and other experts. While some companies may have taken easier paths, potentially compromising safety, we’ve chosen a more cautious approach. Despite the slower progress, I can assure you that whatever we produce will be safe. This commitment to safety is something I find particularly impressive.

Kamil: For those interested, it’s worth noting that Neuralink is currently hiring. They’ve recently secured another round of funding and are actively seeking new talent. This is indeed a glimpse into the future of technology.

Aparna: Earlier, you mentioned an intriguing story about monkeys and reading their brainwaves. This story is related to the AI that’s been implanted in their brains and how it communicates. Could you elaborate on what happens with the models in this context?

Kamil: In our initial approach to decoding brain signals, we utilized a simple model. We had a vector of 1024 electrodes and our goal was to infer whether the monkey was attempting to move the cursor up, down, or click on something. We used static data from what we termed a pre-training session, which was essentially data recorded from the implant. The model was a two-layer perceptron, quite small, and could be trained in about 10 seconds. However, the brain’s signal distribution changes rapidly, so the model was only effective for about 10 to 15 minutes before we observed a degradation in performance. This necessitated the collection of new data and retraining of the model.

Recently, Neuralink has started exploring reinforcement learning-based approaches, which allow for on-the-fly identification and retraining of the model on the implant. During my time at Neuralink, my focus was primarily on the inference side. We trained the model outside the implant, and my role was to make the inference parts work on the implant. This was a significant achievement for us, as we were previously sending data out and back in. Given our battery limitations, performing tasks on the implant was more cost-effective. The ultimate goal was to move the entire training process to the implant.

Every day, our brains produce varying signals due to changes in our moods and environments. These factors could range from being in a noisy place, feeling tired, or engaging in different activities. This results in a constantly shifting distribution of brain signals, which presents a significant challenge. This phenomenon is not only applicable to the brain but also extends to other applications in the medical field.

Aparna: We’ve discussed a wide range of topics, from hardware design to image and video generation, and even brainwaves and implant technology. Thank you so much for these perspectives Kamil!

Thank you to Kamil for his perspectives on these exciting AI topics. To read more about Pear’s AI focus and previous Perspectives in AI talks, visit this page.

Looking back at PearX S19 alum Gradio’s journey, now part of Hugging Face


PearX S19 alum Gradio, which is now part of Hugging Face, has had a momentous few years. They recently launched Version 4.0 of their app and they have quickly become a leading workflow tool in the generative AI infrastructure space. We’re so proud of their success, and wanted to take a look back at the earliest days of the company, why we were excited to partner with Gradio’s founders from day 0, and some of their biggest milestones along the way.

How we met the team:

We first met Gradio’s founding team, Abubakar “Abu” Abid, Ali Abdalla, Ali Abid, and Dawood Khan through Pear’s Fellows program. They were housemates at Stanford at the time, and they came to us with an idea to speed up the process of collecting and labeling data for use with AI and ML. Put simply, they wanted to make it really simple for ML engineers to build and share computer vision models and ultimately to make more reliable models. 

Why we invested:

After meeting the team, we were excited to invest in Gradio from day 0 for a few key reasons:

  • The team: We knew this was the right team to tackle the space. Abu worked on this problems during his PhD in ML at Stanford. The founding team built deep technical products at companies like Tesla and Google. They also had an amazing advisor in Stanford Professor James Zou, who pioneered data valuation methods. 
  • The big market opportunity: Gradio was founded in 2019 when every company was on the precipice of becoming a data-driven or AI company. In 2019 alone, companies were spending $32 billion on data acquisition and labeling, and that number was slated to rise 50% year over year. This easily made this a multi-billion dollar market. 
  • The right product vision: We felt that Gradio could solve the biggest problems that data companies face. At that time, to build AI products, companies had to collect and manually label lots of data and then feed that data into machine learning algorithms and there was a crisis of poor data quality. It was a long and broken process that was ripe for innovation. Gradio’s product leveraged ML research to integrate with a company’s existing data pipeline to maximize the value of the data for ML. Essentially, they created the missing data valuation layer to maximize the potential of data for machine learning. 

How they evolved and what’s next:

They joined our PearX S19 cohort, and through the 14 week PearX cohort, they made huge leaps and bounds with their product. They ran four pilots with different kinds of natural language processing (speech or text) companies, ranging from legal contracts to financial records. Over the course of PearX, these smaller pilots led to landing bigger clients like Wells Fargo and TDBank. They used the learnings from this pilot to steadily expand to cover more areas of machine learning like video. 

Gradio founders meeting investors at Demo Day

At the end of PearX, Abu presented at our Demo Day to a room of tier one investors, and after Demo Day, Gradio successfully raised a seed round. Following the fundraise, our team continued working closely with Gradio’s team to find true product-market fit. This included exploring enterprise solutions across various verticals, which eventually led the team to pursue an Open Source approach to expedite product adoption. Gradio was open sourced, and it became the de facto tool for presenting AI / ML projects to a wide range of audiences. In the end, more than 300,000 demos were built using Gradio. 

In late 2021, they were acquired by Hugging Face. The Pear team partnered closely with Gradio’s leadership throughout the entire acquisition process. They are now a key pillar of Hugging Face, where they provide Hugging Face’s users, developers, and data scientists the tools needed to get high level results and create better models and tools. It’s a machine learning match made in heaven and together, they are building the future of ML. 

Gradio x Hugging Face

We’re excited for even more success from Gradio and will be cheering them on!

Pear Biotech Bench to Business: insights on generative AI in healthcare and biotech with Dr. James Zou

Here at Pear, we specialize in backing companies at the pre-seed and seed stages, and we work closely with our founders to bring their breakthrough ideas, technologies, and businesses from 0 to 1. Because we are passionate about the journey from bench to business, we created this series to share stories from leaders in biotech and academia and to highlight the real-world impact of emerging life sciences research and technologies. This post was written by Pear Partner Eddie and Pear PhD Fellow Sarah Jones.

Today, we’re excited to share insights from our discussion with Dr. James Zou, Assistant Professor of Biomedical Data Science at Stanford University, who utilizes Artificial Intelligence (AI) and Machine Learning (ML) to improve clinical trial design, drug discovery, and large-scale data analysis. We’re so fortunate at Pear to have James serve as a Biotech Industry Advisor for us and for our portfolio companies.

James received his Ph.D. from Harvard in 2014 and was a Simons Research Fellow at UC Berkeley. Prior to accepting a position at Stanford, James worked at Microsoft and focused on statistical machine learning and computational genomics. At Stanford, his lab focuses on making new algorithms that are reliable and fair for a diverse range of applications. As the faculty director of the Stanford AI for Health program, James works across disciplines and actively collaborates with both academic labs and biotech and pharma. 

If you prefer listening, here’s a link to the recording!

Key Takeaways:

1. James and his team employed generative AI not only to predict novel antibiotic compounds, but also to produce a facile ‘recipe’ for chemical synthesis, representing a new paradigm of drug discovery.

  • Antibiotic discovery is challenging for at least a couple of reasons: reimbursement strategies do not incentivize companies to pour resources, time and money into R&D, and antibiotic resistance has made it difficult to create lasting, efficacious products. To accelerate discovery and meet the critical need for new antibiotics, James and his team created a generative AI algorithm that could generate small molecules that were predicted to have high activity. Not only could the model generate chemical structures, but it could also produce the instructions for chemists to make these compounds. By streamlining the process from structure generation to synthesis, James and his team were able to identify a potent antibiotic for pathogens that have developed resistance to existing antibiotics. 
  • These ‘recipes’ that the algorithm generated laid out step-by-step instructions for over 70 lead compounds. After synthesizing and testing the molecules, they found that they achieved a hit rate above 80% and could synthesize 58 novel compounds. Of these 58, they found that six were validated as promising drug candidates. In addition, the model prioritized hits that had robust synthetic protocols and were predicted to have low toxicity. In this way, the model could prioritize certain small molecule features and generate both novel structures and complete recipes. 
  • The generative model in this case used a Monte Carlo Tree search to come up with recipes for new small molecules. The same logic flow and reasoning can easily be applied to other settings. For example, James and his team are working with Stanford spin-outs to apply the algorithm to other diseases such as fibrosis or for applications requiring new fluorescent molecules. 

I think it’s a good, reasonable model for AI and biotech in general to have this close feedback loop, where we start off with some experimental data. In our case, we have some experimental screening data, the actual data used to train the models, and then the model will produce some candidates or some hypotheses. Then we tried to have a more rapid turnaround to do the additional experiments … to further validate the AI’s reasoning and thinking.

2. James’ group has also used generative AI to design clinical trials that aim to be faster, cheaper, more diverse, and more representative.

  • Clinical trials are a critical bottleneck in the pipeline of therapeutic development. Patient enrollment is slow and labor intensive, and  trial design can be biased against underrepresented groups or may exclude patients left out based on criteria that don’t necessarily relate to trial outcome or patient response. To outline trial criteria, a ‘monstrosity’ of a document must be generated to explicitly lay out the rules that will be followed in patient recruitment. 
  • James noted that it’s very hard to balance all of the complicated factors required for a successful trial design. With collaborators at Genentech, James and his team have worked to develop a Generative AI algorithm called Trial Pathfinder that uses historical clinical trials and outcomes to create an optimized trial design, often including a more diverse patient population. Among groups that see more representation and inclusion in AI-generated clinical trials are women, elderly patients, patients from underrepresented groups, and patients who might be a bit sicker. These patients often end up responding just as well without experiencing the predicted adverse events. 
  • When James first started partnering with Genentech, his first goal was to understand the pain points in clinical trial design. He learned that many trials are actually very narrow and essentially recruit for the so-called “Olympic athletes” of patients. He noted one study actually did try to recruit Kobe Bryant and several Olympians. To make clinical trial outcomes more inclusive and representative of a diverse range of patients, one strategy is the use of algorithms that account for such biases. 

If we look more closely at how people design the protocols for clinical trials, often it is based on domain knowledge. But it’s also often quite heuristic and anecdotal, which is why a lot of different teams from different pharma companies–even if they’re looking at drugs of similar mechanisms–often end up with quite different trials and trial designs.

3. AI/ML in biology is only possible because biology is becoming increasingly data driven.

  • The data that we can gather from biological systems is becoming more and more rich and diverse. For example, high resolution spatial transcriptomics or single molecule experiments can now be captured alongside more traditional measurements such as RNA sequencing. Perturbation of biological systems with CRISPR/Cas-9 technology also enables a whole new suite of data that represents an area ripe for AI.
  • Even in the past year, James noted that he has seen tremendous advances in large language models and foundation models on the AI side. It’s also been interesting to see how these advances have enabled new insights in the biotech space. For example, high-throughput perturbation data collected at the single-cell resolution is something that can be extremely compatible with large language models. So far, collaborative efforts between AI and biotech have been extremely fruitful. 
  • As a professor, James and his lab are always pursuing new and exciting research directions. In particular, one project that he’s excited about is fueled by recent progress in spatial biology. As we’ve seen interest skyrocket in single-cell transcriptomics and genomics, researchers have generated huge amounts of data that have led to a variety of different findings and results. However, single cells also reside in different neighborhoods, or local microenvironments. Understanding disease and healthy states in the context of groups of cells may unlock even more insight into how patients may respond to therapies. 
  • Another promising direction James highlighted was the use of large language models to allow researchers to synthesize and analyze information across biological databases. Currently, data is often siloed, and the level of expertise required to utilize individual data sets makes it challenging to work across fields and specialties. 
  • “But this is where we think that language models can really be a unifying framework that can then help us to access data and integrate data from all these different modalities on different knowledge bases. So that’s another thing we’re working on with my students.”

This is why we’re excited about techniques and ideas like large language models that harness data from different modalities, databases, and knowledge bases to help biomedical researchers make faster innovations.

4. Landmark results at the intersection of biology and engineering, such as the Human Genome Project and the discovery of Yamanaka factors for reprogramming stem cells, motivated James to pursue a career in academia and to start his lab at Stanford.

  • James always gravitated towards math and science and started his academic path with an undergraduate major in math. Although he didn’t start out with a focus in biology, he began spending a good deal of time at the Broad Institute during his time at Harvard. At that time, many great biotechnologists were working on projects like sequencing the human genome. James began to learn more about interesting problems at the intersection of AI and biotech. 
  • As he learned about the discovery of Yamanaka factors for reprogramming induced pluripotent stem cells (iPSCs), James was fascinated by the idea that you could take these ‘biological computer programs’ and with only a few instructions, change the state of a cell. Essentially, the biological system became not just something you could study, but something you could engineer.

5. Translation of academic projects needs to happen thoughtfully in collaboration with the right partners.

  • Translation of academic projects can take a few different forms, and not every project is right for translation. James gave a few examples of projects that he knew could move beyond the Stanford campus. One project involved the development of an AI system for assessing heart disease based on cardiac ultrasound videos, or echocardiograms. Millions of these videos are collected each year in the US alone, so it’s one of the most routine and accessible ways to assess cardiovascular disease. 
  • James and his students developed an AI system to help look at these videos and determine outcomes to help clinicians make more accurate diagnoses. Not only did the work result in two publications in the prestigious scientific journal, Nature, but it progressed to clinical trials. 
  • James explained that he clearly sees the larger impact of his work; he wants not only to publish really good papers, but also to work closely with biotech and pharma companies or tech companies to ensure his findings and algorithms can actually impact human health. His focus on translation has led to at least four companies that have been spun out of his group.  
  • “At least one of the things we are doing is developing these algorithms or coming up with some of these potential drug candidates, and to really take it to the next level, either as a viable drug, a platform, or a device that we can take to patients, is something often beyond the scope of an individual PhD.”
  • James enjoys leveraging the community and resources of the Chan-Zuckerberg Biohub, a non-profit initiative aimed at bringing together interdisciplinary leaders to advance our ability to observe and analyze biological systems. Opportunities and communities such as these played a large role in drawing James to the Bay Area. He has actively sought out projects through which he can collaborate with biotech and pharma, investors, and the start-up community.

At that point, it’s really important work. [Getting FDA approval] also requires more resources. That’s where it makes sense for us to have a company that is co-founded by my students. So, for us, in this case, it’s a perfect synergy between doing the early-stage research and development, developing the algorithms to the initial validations and then having the company take over and do the submissions and then do the scaling.

Get to know Dr. James Zou: the person behind the science

James and his wife love to take advantage of all the great outdoors in the Bay Area. Every week, they go on a hike and spend a lot of time swimming or biking. One thing people may be surprised to learn about James is that he used to moonlight as a theater and restaurant reviewer. When he was living in Europe, he would write reviews of movies or restaurants for local English-language newspapers. 

For someone wanting to pursue a similar career to his, James says that it’s a very exciting time to be at the intersection of biology and AI. He encourages students in the space to develop a core technical strength in either field and then begin to explore the synergy between disciplines. 

PearX S19 alum Polimorphic raises $5.6M to continue their work building a constituent relationship management platform for governments

This week, PearX S19 alum, Polimorphic, announced their $5.6m seed round led by M13 with participation from Pear and Shine Capital. We’re really excited about this milestone for Polimorphic because we’ve been able to witness their incredible growth from an idea that came about in their dorm room at MIT to becoming a leading infrastructure player for state, local, and federal government agencies. They’ve demonstrated some amazing traction: 30 governments actively using their platform and they continue to add 15 new customers every month. 

To mark the occasion, we wanted to look back over the last 4+ years of working with the Polimorphic team and some of the major milestones along the way.

How we met the team

We first met Polimorphic’s co-founders, Parth and Daniel, at MIT when they applied for Pear Competition. We invited them to join our upcoming PearX batch in the Summer of 2019. 

Polimorphic CEO & Co-founder Parth presenting at S19 Demo Day at Filoli Gardens

At the time, the founders were working on a product to make sense of government data. The first version was a tool to collect information from federal, state, and local agencies like press releases, legislation and more, making it easy to digest and consume for politicians and constituents alike but especially for younger consumers. 

How they evolved

Polimorphic has evolved quite a bit since 2019. After PearX, the team raised some additional capital and went on a country wide road trip to meet face-to-face with federal, state, and local agencies to learn about their needs. In January 2020, they set off on their trip and visited Iowa, New Hampshire, Washington DC, North Carolina, and Michigan. The pandemic hit during this road trip, and they were even stranded in Michigan for a while! 

Through many months of customer discovery, they learned that their data transparency product was not, in fact, the biggest pain point for governments. Instead, they learned that federal, state, and local government agencies dealt with a tremendous amount of manual work with the number of tasks they deal with – from applications to internal approval workflows to payments processing.

Polimorphic team at S19 Demo Day 

Why we invested

While the product has evolved since 2019, we knew there was a big opportunity here for this team to tackle. We were very optimistic about their unique ability to build in this space and we’re really excited that they uncovered this big opportunity. Some of the reasons we were, and still are, excited about this team include:

  • Market opportunity: We all interact with local, state, and federal governments for many daily tasks. We see a multi billion dollar opportunity in providing software to help federal, state, and local governments manage their day-to-day work. Governments still use a lot of pen and paper in their processes which is why many people view governments as slow moving. But interacting with our government does not need to be a slog.
  • Product vision:  The team saw this big untapped opportunity to digitize and add automation to our interactions with governments. Polimorphic helps digitize applications, payments, internal approval flows and use AI to help automate the busy work for government employees.
  • Founding team: We found Parth and Daniel so compelling. They were two undergraduate engineers thinking deeply about the problems our governments face. Parth’s grandfather worked in local government and he saw first hand the work that went into getting constituents their basic government services. This problem felt really personal to them. They were on a mission to solve these problems and had the grit and tenacity to focus on an otherwise unsexy space. We knew if they could land some customers, the product would be sticky and this has proven to be true.

What’s to come

Over the last four years, we’ve partnered closely with their team as they’ve refined their product roadmap. We helped them identify the biggest hurdles that governments face and encouraged them to really talk to their customers to understand those pain points inside and out. 

We also helped the Polimorphic team fine tune their pitch and raise additional capital. When looking to raise more funding, Parth presented again at our PearX W23 demo day and quickly found a lead investor for this round.

At PearX S23 Demo Day in October 2023

This team has made huge strides since we met them. It’s really inspiring to look back over the last few years to see how they’ve grown in a relatively short amount of time. They went from being stuck in Michigan during the pandemic with no customers to having 30 cities and counties (and growing!) using their software. They’re rapidly growing and are adding a new city to their platform every 2 days. They recently launched a GovGPT, the first gen AI tool that governments have made public to their constituents in the entire country. We’re excited for their future!

The vertical software data gold mine 

Automation opportunities from vertical software’s data gold mine mean it has never been a better time to create purpose-built operational tools for overlooked industries. Plus, our market map of AI-enabled vertical software new entrants. 

Vertical software founders build applications across many industries but with a common mission: to empower expert operators and owners to streamline and grow their businesses with software purpose-built for their own industry. 

Over the past decade, Pear has supported founders building powerful applications for industries ranging from supply chain (Expedock, Beyond Trucks), construction (Gryps, Miter, Doxel), energy (Aurora, Pearl Street) and insurance (Federato) to home services (Conduit), travel (JetInsight, Skipper), agriculture (FarmRaise, Lasso), real estate (Hazel) and live events (Chainpass) – and more. These companies and plenty of others we admire outside of our portfolio have created hundreds of billions of dollars in enterprise value for themselves and for their customers. 

Today, with artificial intelligence capabilities easier than ever to deploy in B2B products, we think it has never been a better time to build vertical software that automates core aspects of customer operations. 

Any new vertical software opportunity — any sector that is not well-served by purpose-built software for industry-specific workflows — now looks even more promising. And, many existing vertical software tools have a rare opportunity to ramp up ACVs, increase stickiness, and build a powerful moat. 

To understand why we might be on the verge of a golden age of intelligently-automated vertical software, we’ll take a look at two problems: First, the ACV problem that has limited vertical software opportunities. Then, the defensibility problem afflicting new AI application entrants. 

The ACV Problem 

Vertical software companies often sell into fragmented industries with many small-to-medium businesses. These businesses operate on thin margins and have limited ability to pay for new operational software. Contract values – and therefore market size – for many verticals have historically been constrained, which means that many sectors remain underserved by purpose-built, cloud-based software.

Historically, vertical software companies have sought to increase the value of their customer relationships by adding bolt-on monetization features like payments or banking. Other vertical software companies have initially sold to the fragmented base of a sector and steadily added operational features to move upmarket to larger customers within their industry. 

In either case, the fundamental margin structure of the end customer remains unchanged, and few vertical software companies can reliably claim to impact their customers’ profitability in a major way. A vertical software customer might love their software’s intuitive UI, centralized system of record, navigable scheduling tools, and modern payment processing system. But these benefits rarely reduce the customer’s overall operating cost in a significant way. 

The Defensibility Problem

Despite the excitement over applications of large language models in late 2022 and early 2023, many initial products were dismissed as “thin wrappers” over an off-the-shelf model. Critics argued that these initial applications lacked product differentiation and long-term defensibility.

At Pear, we believe that proprietary data is one of the keys to a defensible AI application. Proprietary data behind B2B AI applications comes in three forms: 

Many early tools built over groundbreaking LLMs offered no form of proprietary data. At best, some products built over lightly-adapted models offered bronze or silver-level data-based defensibility. But we’ve been on the hunt for game-changing applications that build an advantage in proprietary model-training data from the start.  

The Vertical Software Data Gold Mine 

Traditional vertical software products generate enormous amounts of gold-level data, capture substantial silver-level information, and often themselves aggregate bronze-level data within their products.

Customer business logic flows through vertical software features. From operational decisions and administrative record-keeping to sales and product performance, customers of vertical software deposit reams of data daily into a rich system of record. 

The most impactful B2B applications in the next decade will rigorously structure, mine, and harness gold-level product-generated data to enable workflow automation for their end customers.

Any business process with decisions and steps encoded in a vertical software feature set will be a candidate for automation. We’re most excited about automation that enables faster information processing tied to sales growth or cost-saving opportunities for an end customer: instant diagnosis and repair commissioning for field technicians, predictive inventory capabilities embedded in B2B marketplaces, copilot-style knowledge bases that help small business owners understand the impact of every decision on their bottom line. 

Automation across many business functions will mean that vertical software companies can finally impact their customers’ margin structure – and as a result, help these customers break any linear scaling trap they face when they otherwise expand their business.

Early entrants: A preliminary market map 

We have seen a proliferation of promising AI-enabled vertical software products in a handful of sectors, and we are proud to be the earliest supporters of teams like Expedock, Pearl Street, Gryps, Hazel, and Federato.  

Many initial intelligently automated vertical software products target the largest sectors of the economy (we’ve looked separately at the ecosystem of AI in healthcare companies here). We’ll update this market map over time, and we’re eager to include companies unlocking automation potential in industries that have seen fewer capable purpose-built tools in the past.

What we are looking for 

We hope to support many more founders delivering on a new and bigger promise of vertical software. Standout teams that we currently support – or just simply admire – typically excel on a few dimensions: 

  1. They have an unfair data advantage.
  2. They have identified substantial automation potential. 
  3. They can communicate their value without invoking AI. 

We want to hear from you 

If you share our conviction that we’re entering a new golden age of vertical software and you’re exploring startup ideas that help expert operators streamline and grow their businesses through intelligent automation, we would love to hear from you. Reach out at if you’re working on something impactful.

PearX S20 alumni company Sequel receives FDA approval

On August 3rd, PearX S20 alum Sequel, received FDA approval. Sequel’s co-founders, Greta Meyer and Amanda Calabrese, worked hard to develop their product and work through the FDA clearance process. This can be a grueling process, so it’s truly a huge milestone for Sequel to be able to launch their FDA-approved tampons. We wanted to mark the occasion by looking back on our journey working with the Sequel team.

This image has an empty alt attribute; its file name is xxO0O4cFTmognWsOSyDt7pfSXHs3AZLe3SRJbrkfEzt2iB5jWTAgBnxo8CgygkQb0x1NAYuYoripD2B9qcZxNzwYmQwbt5ToFSkisSJCTYtczDzRuwqS79rs2MNqX5Qn_HyQ3hGaIeJiRRE8hN-obA

Founders, Greta Meyer and Amanda Calabrese

We met Sequel co-founders, Greta Meyer and Amanda Calabrese, when they were still students at Stanford. They were both undergraduate engineering students, where they participated in the LaunchPad d-school course in 2018 to design and launch a product. They were both professional athletes that had lived first hand, menstruation leaks during practice or worse an athletic tournament. Mar was tasked with helping them refine their fundraising pitch and this is how our partnership with Sequel got started. 

Sequel  joined our PearX S20 cohort, right at the start of the pandemic, when they were still called Tempo. And even though it was unexpectedly a virtual cohort, it was an outstanding PearX class, with many other breakout companies like: Seven Starling, Interface Bio, Federato, Expedock, Gryps, and rePurpose Global. 

PearX check-in during Covid.

After meeting Amanda and Greta, we chose to invest in Sequel for a few key reasons:

Big market opportunity:

Greta and Amanda were both superstar athletes and had a pain point: menstruation products are still not reliable for women. While participating in the Launchpad course, they dug into this more to see if others felt the same way. They learned that most women still prefer a tampon to all of the options out there, but they unveiled a common frustration for women: they had to combine their tampons with pads or pantyliners to avoid leaks. Amanda and Greta realized that, while the tampon had been around for ages, it hadn’t seen any innovation in nearly a century. They saw a big opportunity to build a women’s health company that was focused on innovating this big, unmet need for women. 

Their product vision:

We were excited about their mission and vision: to re-engineer the tampon. For their product, the two engineers envisioned a redesign of a tampon in a spiral-shape to fit more comfortably and better absorb periods to prevent leaks. They designed and patented their design, so it’s truly proprietary. We really liked the product innovation and their vision to shake up an old industry that’s dominated by a few huge players like Tampax. 

The founders:

Greta and Amanda were stellar founders and superstar athletes too: Amanda competes for the US Lifesaving Association and Greta played Varsity Lacrosse while at Stanford. They had first hand experience with tampons failing them while being active, and we loved that they were both extremely purpose-driven. 

Amanda and Greta presenting during Demo Day

During PearX, they built out a pretty robust go-to-market strategy, assembled influencers, and started a beta program. They got a quality system up and running to prepare for FDA testing. They were able to beta test with 75+ users before PearX Demo Day. They presented to thousands of investors at Pear Demo Day and raised a seed round from MaC VC, Long Journey Ventures, and others.

Since participating in PearX, they’ve had a number of exciting wins. Greta and Amanda were included on the Forbes 30 under 30 list for manufacturing and industry. Amanda moderated a SXSW panel on content creators and stigmatized spaces. And they received positive press from Fortune, the Wall Street Journal, Forbes and others. 

With FDA approval behind them, we are excited for the Sequel team to be able to focus on commercialization and getting their product out in the world. We know the best is yet to come for this company!

PearX alumni company Via acquired by Justworks!

PearX alumni company, Via, just announced that they’ve been acquired by Justworks. To mark this occasion, we wanted to share a look back on how we met and worked with the Via team over the years. 

Mar first met sisters and Via co-founders Maite and Itziar when they were students at Stanford’s Graduate School of Business. They were enrolled in the Launchpad course where Mar was a guest lecturer. Through the class, they developed an idea to build a marketplace to connect top professionals to short-term project work at different companies around the world. They built strong conviction through the course and we thought they were the perfect fit for as founders of these companies. We invited them to join PearX, our early-stage bootcamp for founders, and partnered with them from then on to build Via. 

We decided to partner with Maite and Itziar for a few major reasons:

We saw a big market opportunity:

The Via co-founders discovered that there was a massive multi-billion dollar need for hyper local employer of record (EOR) and native payroll services for companies in international tech hubs. Through research, they learned that, when companies hire internationally, they typically do so via contractor agreements, but this happens without any truly scalable benefits, compliance, or payroll services. This works for companies that are hiring a small handful of employees in international markets, but it breaks down for companies that are hiring at scale with dozens or even hundreds of employees. Via saw a big opportunity to make that easier for these larger companies.  

Strong ability to execute:

After seeing the big market opportunity, the Via team focused on building a product that met that need. They built deep infrastructure in over a dozen large, international markets, allowing Via to provide the right level of service to multinational Fortune 500 customers. Companies no longer had to spend years laying down the foundation to open a new hub, they could partner directly with Via and launch their new offices in a fraction of the time. They were quickly able to attract a number of top professionals to join companies internationally. We realized the cyclicality of this business model, and at the same time, they were hearing from their corporate customers that there was a big challenge in hiring employees internationally. Starting a new hub in a different country was desirable for many reasons, but payroll, insurance, benefits, and compliance all become very complicated, which prevented many companies from starting international hubs. 

The founders were the right ones to tackle this:

The sisters and co-founders, Maite and Itziar, were the perfect duo to start and run Via. We loved the team because of their deep understanding of their customer’s pain point and their international focus. They are both GSB alums and brought deep business experience to the table: Maite has a background in investment banking at JP Morgan and Itziar was Head of Strategy for Citi Fintech. They also worked in markets like Argentina and Mexico, so they understood the pain points of hiring internationally. 

Via’s work became even more relevant in a post-pandemic world, where there has been a big rise in companies hiring internationally. Put simply, they’ve become the best choice for Fortune 500 customers. This acquisition by Justworks makes sense: together they can offer the Via service at scale. 

We are proud of their journey. After raising an initial pre-seed round after PearX, they realized that it would be hard to build a venture scale business focusing only on short term job opportunities. We huddled with them and they decided it would be best to pivot to the employer side and solve their problem which was more around building a permanent workforce internationally. Maite and Itziar navigated this pivot with rigor and optimism.

The team then scaled out their hyper-local EOR platform, scaled to millions of dollars in annual revenue, and raised a Series A in December 2022. To date, they’ve  raised from an incredible group of investors, including Industry Ventures, Switch VC, Entree Capital, Burst Capital, Pear and more. 

Given the infrastructure that they’ve built, it’s no surprise that they had inbound interest for M&A. We think they’ve found the perfect home in the Justworks team. The acquisition by Justworks provides an ideal platform to scale their joint business internationally allowing any company to become a global organization. Congrats to Maite, Itziar, and the entire Via team!

Anatomy of a successful Artificial Intelligence startup

Founders often ask us what kind of AI company they should start and how to start something long lasting?  

Our thesis on AI and ML at Pear is grounded in the belief that advances in these fields are game-changing, paralleling the advent of the web in the late ’90s. We foresee that AI and ML will revolutionize both enterprise software and consumer applications. A particular area of interest is generative AI, which we believe holds the potential to increase productivity across many verticals by five to ten times. Pear has been investing in AI/ML for many years, and in generative AI more recently. That said, there’s still a lot of noise in this space, which is part of the reason we host a “Perspectives in AI” technical fireside series to cut through the hype, and connect the dots between research and product.

Much of the progress in Generative AI began with the breakthrough invention of the transformer in 2017 by researchers at Google. This innovation combined with the at-scale availability of GPUs in public clouds paved the way for large language models and neural networks to be trained on massive datasets. When these models reach a size of 6 billion parameters or more, they exhibit emergent behavior, performing seemingly intelligent tasks. Coupled with training on mixed domain data such as the pile dataset, these models become general-purpose, capable of various tasks including code generation, summarization, and other text-based functions. These are still statistical models with non zero rates of error or hallucination but they are nevertheless a breakthrough in the emergence of intelligent output.

Another related advancement is the ability to employ these large foundational models and customize them through transfer learning to suit specific tasks. Many different techniques are employed here, but one that is particularly efficient and relevant to commercial applications is fine tuning using Low Rank Adaptation. LoRA enables the creation of multiple smaller fine tuned models that can be optimized for a particular purpose or character, and function in conjunction with the larger model to provide a more effective and efficient output. Finally one of the most important recent innovations that allowed the broad public release of LLMs has been RLHF and RLAIF to create models that are aligned with company-specific values or use-case-specific needs. Collectively these breakthroughs have catalyzed the capabilities we’re observing today, signifying a rapid acceleration in the field.

Text is, of course, the most prevalent domain for AI models, but significant progress has been made in areas like video, image, vision, and even biological systems. This year, in particular, marks substantial advancements in generative AI, including speech and multimodal models. The interplay between open-source models (represented in white in the figure below) and commercial closed models is worth noting. Open-source models are becoming as capable as their closed counterparts, and the cost of training these models is decreasing.

Our thesis on AI breaks down into three parts: 1. applications along with foundation / fine tuned models, 2. data, tooling and orchestration and 3. infrastructure which includes cloud services software and hardware. At the top layer we believe the applications that will win in the generative AI ecosystem will be architected using ensembles of task specific models that are fine tuned using proprietary data (specific to each vertical, use case, and user experience),along with retrieval augmentation. OrbyAI is an early innovation leader in this area of AI driven workflow automation. It is extremely relevant and useful for enterprises.We also believe that tooling for integrating, orchestrating, evaluating/testing, securing and continuously deploying model based applications is a separate investment category. Nightfall understands this problem well and is focused on tooling for data privacy and security of composite AI applications. Finally, we see great opportunity in infrastructure advances at the software, hardware and cloud services layer for efficient training and inference at larger scales across different device form factors. There are many diverse areas within infrastructure from specialized AI chips to high bandwidth networking to novel model architectures. Quadric is a Pear portfolio company working in this space.

Successful entrepreneurs will focus on using a mixture of specialized models fine tuned using proprietary or personal data, to a specific workflow along with retrieval augmentation and prompt engineering techniques to build reliable, intelligent applications that automate previously cumbersome processes. For most enterprise use cases the models will be augmented by a retrieval system to ensure a fact basis as well as explainability of results. We discuss open source models in this context because these are more widely accessible for sophisticated fine tuning, and they can be used in private environments for access to proprietary data. Also they are often available in many sizes enabling applications with more local and edge based form factors. Open source models are becoming progressively more capable with new releases such as Llama2 and the cost of running these models is also going down. 

When we talk about moats, we think it’s extremely important that founders have compelling insight regarding the specific problem they are solving and experience with go-to market for their use case. This is important for any start up, but in AI access to proprietary data and skilled human expertise are even more important for building a moat. Per our thesis, fine tuning models for specific use cases using proprietary data and knowledge is key for building a moat. Startups that solve  major open problems in AI such as providing scalable mechanisms for data integration, data privacy, improved accuracy, safety, and compliance for composite AI applications can also have an inherent moat.

A high level architecture or “Anatomy of a modern AI application” often involves preprocessing data, chunking it and then using an embedding model, putting those embeddings into a database, creating an index or multiple indices and then at runtime, creating embeddings out of the input and then essentially searching against the index with appropriate curation and ranking of results. AI applications pull in other sources of information and data as needed using traditional APIs and databases, for example for real time or point in time information, referenceable facts or to take actions. This is referred to as RAG or retrieval augmented generation. Most applications require prompt engineering for many purposes including formatting the model input/output, adding specific instructions, templates, and providing examples to the LLM. The retrieved information combined with prompt engineering is fed to an LLM or a set of LLMs/ mixture of large language models, and the synthesized output is communicated back to the user. Input and output validation, rate limiting and other privacy and security mechanisms are inserted at the input and output of LLMs. I’ve bolded the Embedding model, and the LLMs, because those benefit from fine tuning.

In terms of applications that are ripe for disruption from generative AI, there are many. First of all, the idea of personalized “AI Assistants” for consumers broadly will likely represent the most powerful shift in the way we use computing in the future. Shorter term we expect specific “assistants” for major functional areas. In particular software development and the engineering function overall will likely be the first adopter of AI assistants for everything from code development to application troubleshooting. It may be best to think of this area in terms of the jobs to be done (e.g., SWE, Test/QA, SRE etc), while some of these are using generativeAI today, there is much more potential still. A second closely related opportunity area is data and analytics which is dramatically simplified by generative AI. Additional rich areas for building generative AI applications are all parts of CRM systems for marketing, sales, and support, as well as recruiting, learning/education and HR functions. Sellscale is one of our latest portfolio companies accelerating sales and marketing through generative AI. In all of these areas we think it is important for startups to build deep moats using proprietary data and fine tuning domain specific models. 

We also clearly see applications in healthcare, legal, manufacturing, finance, insurance, biotech and pharma verticals all of which have significant workflows that are rich in text, images or numbers that can benefit greatly from artificial intelligence. Federato is a Pear portfolio company that is applying AI to risk optimization for the insurance industry while VizAI uses AI to connect care teams earlier, increase speed of diagnosis and improve clinical care pathways starting with Stroke detection. These verticals are also regulated and have a higher bar for accuracy, privacy and explainability all of which provide great opportunities for differentiation and moats. Separately, media, retail and gaming verticals offer emerging opportunities for generative AI that have more of a consumer / creator goto market. The scale and monetization profile of this type of vertical may be different from highly regulated verticals. We also see applications in Climate, Energy and Robotics longer term.

Last but not least, at Pear we believe some of the biggest winners from generative AI will be at the infrastructure and tooling layers of the stack. Startups solving problems in systems to make inference and training more efficient, pushing the envelope with context lengths, enabling data integration, model alignment, privacy, and safety and building platforms for model evaluation, iteration and deployment should see a rapidly growing market. 

We are very excited to partner with the entrepreneurs who are building the future of these workflows. AI, with its recent advances, offers a new capability that is going to force a rethinking of how we work and what parts can be done more intelligently. We can’t wait to see what pain points you will address!